8-K: ZyVersa Therapeutics Faces Nasdaq Delisting, Plans OTC Market Move

ZyVersa Therapeutics, Inc. received a final determination from Nasdaq to deny its appeal for continued listing, leading to a suspension of trading and planned delisting, with the company intending to move to the Pink Limited Market.

Summary

• ZyVersa Therapeutics, Inc. (ZVSA) received a determination letter from The Nasdaq Stock Market LLC on July 15, 2025, denying its request to continue listing on The Nasdaq Capital Market.
• The denial stems from the company's non-compliance with Nasdaq's minimum bid price requirements under Listing Rule 5550(a)(2).
• The company had previously appealed the Staff's decision and requested an exception to complete its compliance plan, which the Nasdaq Hearings Panel has now denied.
• Trading in ZyVersa's common stock is scheduled to be suspended at the open of trading on July 17, 2025.
• As a result of the suspension and expected delisting, the company anticipates a very limited market for its shares, potential difficulty for stockholders to sell, and adverse effects on the trading price.
• ZyVersa plans to apply for trading on the Pink Limited Market maintained by the OTC Markets Group Inc. to mitigate the risk of delisting.
• The company's common stock is expected to begin trading on the Pink Limited Market on or about July 17, 2025, continuing under the symbol ZVSA.
• The company has 15 days from the Panel's decision date to request a review by the Nasdaq Council.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to the imminent delisting from Nasdaq, suspension of trading, and the anticipated adverse impact on share liquidity and price. The plan to move to the OTC market is a mitigation strategy, not a positive development in itself.

Positives

• The company plans to apply for trading on the Pink Limited Market maintained by the OTC Markets Group Inc. to mitigate the risk of delisting from Nasdaq, aiming to provide some continued market for its shares.

Negatives

• Nasdaq Hearings Panel denied the company's appeal to continue its listing on The Nasdaq Capital Market.
• The company is not in compliance with Nasdaq's minimum bid price requirements.
• Trading in the company's common stock will be suspended at the open of trading on July 17, 2025.
• The expected delisting from Nasdaq will result in a very limited market for the company's shares.
• Stockholders may find it difficult to sell their shares of common stock.
• The trading price of the company's securities, if any, may be adversely affected.

Risks

• There may be a very limited market in which the company's shares are traded following delisting.
• The company's stockholders may find it difficult to sell their shares of common stock.
• The trading price of the company's securities, if any, may be adversely affected by the suspension and delisting.

Future Outlook

ZyVersa Therapeutics plans to apply for trading on the Pink Limited Market maintained by the OTC Markets Group Inc. to mitigate the impact of the Nasdaq delisting. Trading on the Pink Limited Market is expected to commence on or about July 17, 2025, under the existing symbol ZVSA.

Management Comments

• Stephen Glover, Chief Executive Officer, signed the report on behalf of ZyVersa Therapeutics, Inc.

Industry Context

The delisting of ZyVersa Therapeutics from Nasdaq highlights the stringent listing requirements of major exchanges, particularly for smaller biotechnology companies that may struggle to maintain minimum bid prices. While specific to ZyVersa, such delistings can impact investor confidence in the broader small-cap biotech sector, emphasizing the importance of financial stability and market capitalization for continued exchange listing.

Comparison to Industry Standards

• Delisting from a major exchange like Nasdaq is a significant negative event that contrasts sharply with the listing status of most established and growing companies in the biotechnology sector, which typically maintain Nasdaq or NYSE listings for liquidity and investor visibility.
• Maintaining a minimum bid price is a standard requirement across major exchanges, and failure to do so, leading to delisting, indicates a performance issue relative to industry peers that successfully meet these ongoing listing standards.

Legal Proceedings

• The company is undergoing a regulatory process with The Nasdaq Stock Market LLC regarding its non-compliance with minimum bid price requirements, which has resulted in a determination to delist its securities.

Stakeholder Impact

• Shareholders: Will face a very limited market for their shares, potential difficulty in selling shares, and an adversely affected trading price due to the suspension and delisting from Nasdaq.

Next Steps

• The company has 15 days from the date of the Panel's decision (July 15, 2025) to request that the Nasdaq Council review the Panel's decision.
• The Nasdaq Council may, on its own motion, determine to review the Panel's decision within 45 calendar days after issuance of the Letter.
• The company plans to apply for trading on the Pink Limited Market maintained by the OTC Markets Group Inc.
• The company's common stock is expected to begin trading on the Pink Limited Market on or about July 17, 2025.

Key Dates

Recommendation

Keywords

ZyVersa Therapeutics, ZVSA, Nasdaq delisting, OTC Markets, Pink Limited Market, minimum bid price, stock suspension, SEC filing, 8-K, biotechnology, pharmaceuticals